ATE79270T1 - Verwendung von interzellularen adhaesionsmolek¨len und deren bindungsliganden bei der behandlung von asthma. - Google Patents

Verwendung von interzellularen adhaesionsmolek¨len und deren bindungsliganden bei der behandlung von asthma.

Info

Publication number
ATE79270T1
ATE79270T1 AT90104423T AT90104423T ATE79270T1 AT E79270 T1 ATE79270 T1 AT E79270T1 AT 90104423 T AT90104423 T AT 90104423T AT 90104423 T AT90104423 T AT 90104423T AT E79270 T1 ATE79270 T1 AT E79270T1
Authority
AT
Austria
Prior art keywords
molecules
asthma
treatment
intercellular
adhaesion
Prior art date
Application number
AT90104423T
Other languages
English (en)
Inventor
Craig D Wegner
Robert H Gundel
Robert Rothlein
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of ATE79270T1 publication Critical patent/ATE79270T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT90104423T 1989-03-09 1990-03-08 Verwendung von interzellularen adhaesionsmolek¨len und deren bindungsliganden bei der behandlung von asthma. ATE79270T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32101889A 1989-03-09 1989-03-09
US32123789A 1989-03-09 1989-03-09
US32123989A 1989-03-09 1989-03-09
US32448189A 1989-03-16 1989-03-16
US40140989A 1989-09-01 1989-09-01

Publications (1)

Publication Number Publication Date
ATE79270T1 true ATE79270T1 (de) 1992-08-15

Family

ID=27541038

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90104423T ATE79270T1 (de) 1989-03-09 1990-03-08 Verwendung von interzellularen adhaesionsmolek¨len und deren bindungsliganden bei der behandlung von asthma.

Country Status (13)

Country Link
EP (1) EP0387701B1 (de)
JP (1) JP3119483B2 (de)
KR (1) KR0177519B1 (de)
AT (1) ATE79270T1 (de)
AU (1) AU638450B2 (de)
CA (1) CA2047721C (de)
DE (1) DE69000248T2 (de)
DK (1) DK0387701T3 (de)
ES (1) ES2035668T3 (de)
GR (1) GR3006073T3 (de)
HU (1) HU216313B (de)
NZ (1) NZ232868A (de)
WO (1) WO1990010453A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
ES2141076T3 (es) 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
EP0468257B1 (de) * 1990-07-20 1999-09-01 Bayer Corporation Multimere Formen des menschlichen Rhinovirus-Rezeptorproteins
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
EP0551400A4 (en) * 1990-10-03 1993-10-13 Boehringer Ingelheim Pharmaceuticals Inc. Method for treating inflammation using anti-idiotypic antibodies
CA2056143A1 (en) * 1990-11-28 1992-05-29 Michael S. Diamond The mac-1 binding site of icam-1
EP0507187B1 (de) * 1991-04-03 1996-12-04 Boehringer Ingelheim Pharmaceuticals Inc. Verfahren zur Hemmung der Sauerstofftoxizität in den Lungen
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
AU663332B2 (en) * 1991-07-31 1995-10-05 Baylor College Of Medicine Use of endothelial-leukocyte adhesion molecule-1 and antibodies thereto in the treatment of asthma
CA2120500A1 (en) * 1991-10-01 1993-04-15 Mitsuaki Isobe Preventing allograft rejection with antibodies to adhesion molecules
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5708141A (en) * 1992-05-11 1998-01-13 Corvas International, Inc. Neutrophil inhibitors
RU94046450A (ru) * 1992-06-22 1996-10-10 Майлз Инк. (US) Мультимерная icam-i, способ усиления связывания icam-i с лигандом, фармацевтическая композиция, способ индукции декансидации, способ необратимого ингибирования заражения клеток
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
CA2898314A1 (en) 2001-07-19 2003-07-31 Perian Therapeutics, Inc. Multimeric proteins and methods of making and using same
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2080044T3 (es) * 1987-05-04 1996-02-01 Dana Farber Cancer Inst Inc Moleculas de adhesion intercelular y sus ligandos de fijacion.
EP0314863B1 (de) * 1987-11-02 1994-12-07 Baylor College Of Medicine Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen
CA1341055C (en) * 1987-12-08 2000-07-18 Alan Mcclelland Transfectant cell lines which express the major human rhinovirus receptor

Also Published As

Publication number Publication date
AU5349990A (en) 1990-10-09
DE69000248T2 (de) 1993-01-07
GR3006073T3 (de) 1993-06-21
ES2035668T3 (es) 1993-04-16
EP0387701A1 (de) 1990-09-19
DK0387701T3 (da) 1992-12-07
HU216313B (hu) 1999-06-28
KR920700667A (ko) 1992-08-10
EP0387701B1 (de) 1992-08-12
DE69000248D1 (de) 1992-09-17
KR0177519B1 (ko) 1999-03-20
AU638450B2 (en) 1993-07-01
JP3119483B2 (ja) 2000-12-18
WO1990010453A1 (en) 1990-09-20
NZ232868A (en) 1995-05-26
CA2047721A1 (en) 1990-09-10
JPH04504127A (ja) 1992-07-23
HU902883D0 (en) 1991-12-30
HUT65843A (en) 1994-07-28
CA2047721C (en) 2004-01-06

Similar Documents

Publication Publication Date Title
ATE79270T1 (de) Verwendung von interzellularen adhaesionsmolek¨len und deren bindungsliganden bei der behandlung von asthma.
ATE172988T1 (de) Die mac-1-bindungsstelle von icam-1
ATE291011T1 (de) Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
ATE73045T1 (de) Verfahren zur herstellung von holzspanplatten u.dgl. und entsprechende doppelbandpressen.
DE69830336D1 (de) Ein kovalentes konjugat von clozapine und einer fettsäure und dessen verwendung zur behandlung von schizophrenie
DE69212620D1 (de) Verwendung von Glycosaminoglycanen zur Behandlung von diabetischer Nephropathie und diabetischer Neuropathie
ATE238047T1 (de) Verwendung von n,n-bis (phenylcarbamoylmethyl) dimethylammoniumchlorid und derivaten davon zur behandlung von chronischem schmerz
DE69523654D1 (de) Verwendung von Ascorbyl-gamma-Linolenat und von Ascorbyl-dihomo-gamma-linolenat zur Behandlung von Asthma, Krebs, kardiovaskulären und inflammatorischen Erkrankungen
DE3876688D1 (de) Thixothrope anstrichmittelzusammensetzung und gegenstaende damit.
DE69432429D1 (de) Palladiumkomplexe und verfahren zu ihrer verwendung in der behandlung von tumoren und psoriasis
DE69829763D1 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
DE69833297D1 (de) Substituierte Pyridylmethylpiperazin- und piperidinderivate, deren Herstellung und deren Verwendung in der Behandlung von Erkrankungen des Zentralnervensystems (ZNS)
DE69734296D1 (de) Neue dikaffeoylchinasäurederivate und deren verwendung zur behandlung von hepatitis b
DE3483989D1 (de) Cumarinderivate, diese enthaltende pharmazeutische zubereitungen und ihre verwendung bei der behandlung von krebs.
ATE227278T1 (de) Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression
DE59009684D1 (de) Mittel zur Verbesserung der Wiederfindung von Annexinen.
DE69832722D1 (de) L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen
ATE113939T1 (de) Verfahren zur herstellung von cephalosporin und zwischenverbindungen.
ATA125788A (de) Neue derivate von 5-aminomethyl-2-furanmethanol, ihre herstellung und verwendung
DE69120197D1 (de) Verfahren für die Bestimmung von Stabilität von Ölgemischen, einschliesslich Schieferöl und dessen Fraktionen
DE3586420D1 (de) Verwendung von dihydropyridinen zur behandlung und praevention von arteriosklerose.
DE69718168D1 (de) Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv
DE68900867D1 (de) 1,5-benzothiazepinderivate, ihre herstellung und ihre verwendung in der behandlung von kardiovasculaeren stoerungen.
ATE122886T1 (de) Verwendung von 1,4-dihydropyridin-derivaten in der behandlung von alkoholsucht.
DE69629931D1 (de) 1-(hetero)aryl-4-(kondensiertes thiazol-2-ylalkyl)-piperazin derivate, deren herstellung und deren verwendung in der behandlung von 5-ht1a-rezeptor vermittelten krankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time